Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test

Executive Summary

Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.

You may also be interested in...



Aerie Looks To Grow Its Two Glaucoma Products In Tandem

The approval of combo therapy Rocklatan gives Aerie two approved glaucoma products; Rhopressa quickly attained wide market access in the US and Aerie expects Rocklatan to fare the same.

Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys

The latest drug development news and highlights from our US FDA Performance Tracker.

Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy

US FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee votes in favor of efficacy of proposed glaucoma treatment, but several say only in patients with baseline intraocular pressure less than 25 mmHg.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129917

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel